Commonly Used Opioids in Pain Management Market 2016 Sep 2016 | Page 3

Pain Management- New Discoveries And Treatment Options In
Abuse Deterrent Era
Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are
approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxaydo) and
are expected to provide improvements over existing formulations for abuse deterrent purpose. But they
have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets
or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse
(through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant
value to create “Abuse Deterrent Era” in the coming time.

Around 20 plus Abuse Deterrent Formulations of opioids are in the pipeline and most of them are ER
formulations which use different AD tech platform to make its ADF. Amongst these pipeline ADF drugs, 6
are of Hydrocodone, 8 are of Morphine and 6 are of Oxycodone based ADF formulations.
Request for Sample at http://www.reportsnreports.com/contacts/requestsample.aspx?name=679333.